MedTrace Logo

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

NCT05521997 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-03-13

No results posted yet for this study

Summary

Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.

Conditions

  • Advanced Cervical Carcinoma
  • Cervical Cancer
  • Cervix Cancer
  • Cancer of the Cervix

Interventions

DRUG

Telaglenastat

-800 mg twice per day by mouth

RADIATION

Radiation treatment

* Standard of care * External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy.

DRUG

Cisplatin

* Standard of care * Weekly administration of cisplain

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Calithera Biosciences, Inc

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Julie K Schwarz, M.D., Ph.D. · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2032-10-07
Completion
2032-10-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05521997 on ClinicalTrials.gov